M&A / Deals Eli Lilly outlays $7.8bn to acquire sleep drug biotech Centessa Pharmaceutical TechnologyWhether the deal reaches its full value hinges on US regulatory milestones for Centessa's lead candidate, cleminorexton.M&A / DealsNeuroscienceRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) Pharmaceutical Technology Whether the deal reaches its full value hinges on US regulatory milestones for Centessa’s lead candidate, cleminorexton. M&A / DealsNeuroscienceRead full story Post navigation Previous: Symeres and Ambagon collaborate for colorectal cancer moleculesNext: FDA points to liver injury with Amgen’s Tavneos Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
